Switch to:
Also traded in: Argentina, Belgium, Brazil, Chile, Germany, Mexico, Sweden, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.33
NYSE:PFE's Cash to Debt is ranked lower than
74% of the 789 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. NYSE:PFE: 0.33 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:PFE' s Cash to Debt Range Over the Past 10 Years
Min: 0.22  Med: 0.9 Max: 3.47
Current: 0.33
0.22
3.47
Equity to Asset 0.36
NYSE:PFE's Equity to Asset is ranked lower than
83% of the 722 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. NYSE:PFE: 0.36 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:PFE' s Equity to Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.47 Max: 0.66
Current: 0.36
0.36
0.66
Interest Coverage 10.20
NYSE:PFE's Interest Coverage is ranked lower than
73% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 104.15 vs. NYSE:PFE: 10.20 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:PFE' s Interest Coverage Range Over the Past 10 Years
Min: 5.27  Med: 9.95 Max: 24.84
Current: 10.2
5.27
24.84
F-Score: 5
Z-Score: 2.05
M-Score: -2.53
WACC vs ROIC
8.52%
11.74%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 23.45
NYSE:PFE's Operating margin (%) is ranked higher than
85% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.25 vs. NYSE:PFE: 23.45 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:PFE' s Operating margin (%) Range Over the Past 10 Years
Min: 14.53  Med: 22.93 Max: 29.44
Current: 23.45
14.53
29.44
Net-margin (%) 11.61
NYSE:PFE's Net-margin (%) is ranked higher than
69% of the 737 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. NYSE:PFE: 11.61 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:PFE' s Net-margin (%) Range Over the Past 10 Years
Min: 11.61  Med: 17.05 Max: 42.65
Current: 11.61
11.61
42.65
ROE (%) 9.64
NYSE:PFE's ROE (%) is ranked higher than
62% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.55 vs. NYSE:PFE: 9.64 )
Ranked among companies with meaningful ROE (%) only.
NYSE:PFE' s ROE (%) Range Over the Past 10 Years
Min: 9.29  Med: 12.16 Max: 28.2
Current: 9.64
9.29
28.2
ROA (%) 3.64
NYSE:PFE's ROA (%) is ranked higher than
52% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. NYSE:PFE: 3.64 )
Ranked among companies with meaningful ROA (%) only.
NYSE:PFE' s ROA (%) Range Over the Past 10 Years
Min: 3.64  Med: 6.22 Max: 16.63
Current: 3.64
3.64
16.63
ROC (Joel Greenblatt) (%) 48.13
NYSE:PFE's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.88 vs. NYSE:PFE: 48.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:PFE' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 40.74  Med: 57.28 Max: 82.01
Current: 48.13
40.74
82.01
Revenue Growth (3Y)(%) 2.40
NYSE:PFE's Revenue Growth (3Y)(%) is ranked lower than
59% of the 609 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.20 vs. NYSE:PFE: 2.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:PFE' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.5  Med: 3.8 Max: 19.2
Current: 2.4
-2.5
19.2
EBITDA Growth (3Y)(%) -3.40
NYSE:PFE's EBITDA Growth (3Y)(%) is ranked lower than
70% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.60 vs. NYSE:PFE: -3.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:PFE' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -4.7  Med: 4.4 Max: 35.6
Current: -3.4
-4.7
35.6
EPS Growth (3Y)(%) -2.60
NYSE:PFE's EPS Growth (3Y)(%) is ranked lower than
63% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. NYSE:PFE: -2.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:PFE' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -26.8  Med: 1.9 Max: 90.5
Current: -2.6
-26.8
90.5
» NYSE:PFE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

PFE Guru Trades in Q4 2015

Jim Simons 7,985,341 sh (New)
David Tepper 2,412,250 sh (New)
Alan Fournier 3,027,040 sh (New)
Andreas Halvorsen 7,424,690 sh (New)
Jana Partners 9,168,818 sh (New)
John Paulson 632,700 sh (New)
Lee Ainslie 11,298,953 sh (+62.86%)
Pioneer Investments 8,180,008 sh (+45.62%)
Ruane Cunniff 14,850 sh (+31.39%)
Mairs and Power 3,897,329 sh (+27.20%)
Ray Dalio 434,408 sh (+25.66%)
Paul Tudor Jones 34,900 sh (+23.32%)
T Rowe Price Equity Income Fund 14,525,000 sh (+15.28%)
John Buckingham 76,884 sh (+5.92%)
Diamond Hill Capital 10,721,361 sh (+3.28%)
Ken Fisher 32,334,417 sh (+1.28%)
Murray Stahl 65,941 sh (+0.30%)
Richard Pzena 2,161,593 sh (+0.08%)
Ronald Muhlenkamp 38,409 sh (unchged)
Robert Bruce 455,332 sh (unchged)
George Soros 1,290,000 sh (unchged)
David Carlson 300,000 sh (unchged)
David Dreman Sold Out
Louis Moore Bacon Sold Out
Joel Greenblatt Sold Out
Jeff Auxier 86,224 sh (-0.11%)
Barrow, Hanley, Mewhinney & Strauss 53,862,996 sh (-0.76%)
Manning & Napier Advisors, Inc 735,031 sh (-2.99%)
Mario Gabelli 706,956 sh (-3.16%)
Charles Brandes 5,639,537 sh (-3.82%)
Jeremy Grantham 5,978,092 sh (-5.01%)
Kahn Brothers 1,569,873 sh (-6.05%)
RS Investment Management 1,634,205 sh (-10.20%)
Prem Watsa 210,000 sh (-10.64%)
Vanguard Health Care Fund 8,872,226 sh (-29.31%)
Keeley Asset Management Corp 77,749 sh (-38.66%)
NWQ Managers 1,967,718 sh (-54.84%)
Leon Cooperman 1,295,600 sh (-73.18%)
John Burbank 161,742 sh (-87.49%)
Dodge & Cox 2,243,178 sh (-95.04%)
First Eagle Investment 135,661 sh (-97.77%)
» More
Q1 2016

PFE Guru Trades in Q1 2016

David Dreman 5,820 sh (New)
Joel Greenblatt 1,577,263 sh (New)
Paul Singer 3,925,482 sh (New)
John Burbank 3,171,356 sh (+1860.75%)
John Paulson 1,378,100 sh (+117.81%)
Jana Partners 13,460,304 sh (+46.81%)
Keeley Asset Management Corp 104,500 sh (+34.41%)
Pioneer Investments 10,669,986 sh (+30.44%)
NWQ Managers 2,518,601 sh (+28.00%)
Mairs and Power 4,402,543 sh (+12.96%)
Ray Dalio 460,039 sh (+5.90%)
Diamond Hill Capital 11,245,591 sh (+4.89%)
David Tepper 2,512,250 sh (+4.15%)
First Eagle Investment 141,061 sh (+3.98%)
Murray Stahl 68,472 sh (+3.84%)
John Buckingham 78,483 sh (+2.08%)
T Rowe Price Equity Income Fund 14,730,900 sh (+1.42%)
Richard Pzena 2,187,104 sh (+1.18%)
RS Investment Management 1,644,965 sh (+0.66%)
Ronald Muhlenkamp 38,409 sh (unchged)
Prem Watsa 210,000 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Louis Moore Bacon 200,000 sh (unchged)
John Paulson 800,000 sh (unchged)
David Carlson 300,000 sh (unchged)
Leon Cooperman Sold Out
Alan Fournier Sold Out
Barrow, Hanley, Mewhinney & Strauss 53,724,766 sh (-0.26%)
Jeff Auxier 85,899 sh (-0.38%)
Manning & Napier Advisors, Inc 726,260 sh (-1.19%)
Ken Fisher 31,746,148 sh (-1.82%)
Charles Brandes 5,536,325 sh (-1.83%)
Jeremy Grantham 5,800,868 sh (-2.96%)
Kahn Brothers 1,442,543 sh (-8.11%)
Ruane Cunniff 12,442 sh (-16.22%)
Vanguard Health Care Fund 7,267,526 sh (-18.09%)
Mario Gabelli 537,011 sh (-24.04%)
Lee Ainslie 8,232,303 sh (-27.14%)
Paul Tudor Jones 14,600 sh (-58.17%)
Dodge & Cox 929,604 sh (-58.56%)
Jim Simons 2,416,341 sh (-69.74%)
Andreas Halvorsen 1,117,592 sh (-84.95%)
» More
Q2 2016

PFE Guru Trades in Q2 2016

Tom Russo 19,900 sh (New)
David Dreman 29,962 sh (+414.81%)
Lee Ainslie 18,426,824 sh (+123.84%)
Jeremy Grantham 12,281,814 sh (+111.72%)
Paul Tudor Jones 21,500 sh (+47.26%)
Pioneer Investments 15,488,287 sh (+45.16%)
Joel Greenblatt 1,938,282 sh (+22.89%)
Ray Dalio 560,639 sh (+21.87%)
Diamond Hill Capital 11,646,559 sh (+3.57%)
Mairs and Power 4,482,288 sh (+1.81%)
Jeff Auxier 85,899 sh (unchged)
Prem Watsa 210,000 sh (unchged)
Robert Bruce 455,332 sh (unchged)
David Carlson 300,000 sh (unchged)
Vanguard Health Care Fund Sold Out
David Tepper Sold Out
Jana Partners Sold Out
Andreas Halvorsen Sold Out
Paul Singer Sold Out
Richard Pzena 2,186,404 sh (-0.03%)
Ken Fisher 31,724,530 sh (-0.07%)
Murray Stahl 68,255 sh (-0.32%)
Ronald Muhlenkamp 37,049 sh (-3.54%)
Mario Gabelli 517,941 sh (-3.55%)
John Buckingham 75,656 sh (-3.60%)
Keeley Asset Management Corp 100,600 sh (-3.73%)
T Rowe Price Equity Income Fund 13,941,800 sh (-5.36%)
Charles Brandes 5,231,096 sh (-5.51%)
Barrow, Hanley, Mewhinney & Strauss 48,981,192 sh (-8.83%)
Manning & Napier Advisors, Inc 651,040 sh (-10.36%)
Dodge & Cox 830,581 sh (-10.65%)
NWQ Managers 2,095,468 sh (-16.80%)
Kahn Brothers 1,156,866 sh (-19.80%)
Jim Simons 1,745,400 sh (-27.77%)
First Eagle Investment 76,061 sh (-46.08%)
RS Investment Management 793,005 sh (-51.79%)
Ruane Cunniff 5,930 sh (-52.34%)
John Paulson 510,400 sh (-62.96%)
John Burbank 420,192 sh (-86.75%)
» More
Q3 2016

PFE Guru Trades in Q3 2016

Jim Simons 8,566,241 sh (+390.79%)
Lee Ainslie 21,380,155 sh (+16.03%)
NWQ Managers 2,360,862 sh (+12.67%)
Ray Dalio 626,339 sh (+11.72%)
Richard Pzena 2,329,636 sh (+6.55%)
Diamond Hill Capital 11,856,263 sh (+1.80%)
Mairs and Power 4,555,073 sh (+1.62%)
Ken Fisher 31,836,368 sh (+0.35%)
David Carlson 300,000 sh (unchged)
David Dreman 29,962 sh (unchged)
Prem Watsa 210,000 sh (unchged)
Eric Mindich 3,050,000 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Ruane Cunniff Sold Out
Tom Russo Sold Out
T Rowe Price Equity Income Fund 13,875,000 sh (-0.48%)
Manning & Napier Advisors, Inc 645,026 sh (-0.92%)
Jeff Auxier 85,015 sh (-1.03%)
John Burbank 409,366 sh (-2.58%)
Ronald Muhlenkamp 36,034 sh (-2.74%)
Mario Gabelli 502,386 sh (-3.00%)
Murray Stahl 65,882 sh (-3.48%)
Barrow, Hanley, Mewhinney & Strauss 47,267,043 sh (-3.50%)
Charles Brandes 5,032,007 sh (-3.81%)
John Buckingham 72,763 sh (-3.82%)
Dodge & Cox 773,142 sh (-6.92%)
Keeley Asset Management Corp 91,630 sh (-8.92%)
Pioneer Investments 13,857,332 sh (-10.53%)
First Eagle Investment 66,061 sh (-13.15%)
Paul Tudor Jones 17,200 sh (-20.00%)
Kahn Brothers 919,757 sh (-20.50%)
Joel Greenblatt 1,158,937 sh (-40.21%)
Jeremy Grantham 6,716,818 sh (-45.31%)
John Paulson 252,000 sh (-50.63%)
» More
» Details

Insider Trades

Latest Guru Trades with PFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:MRK, NYSE:NVS, NYSE:SNY, NYSE:ABBV, NYSE:BMY, OTCPK:GLAXF, OTCPK:BAYRY, NYSE:LLY, NYSE:JNJ, NYSE:AZN, OTCPK:ALPMY, OTCPK:OTSKF, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHPTY, OTCPK:SNPHY, OTCPK:PTKFY, NAS:GWPH » details
Traded in other countries:PFE.Argentina, PFEBC.Belgium, PFIZ34.Brazil, PFE.Chile, PFE.Germany, PFE.Mexico, PFE.Sweden, PFE.Switzerland, PFZ.UK,
Pfizer Inc is a research-based biopharmaceutical company. The Company has five operating segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health; and Consumer Healthcare.

Pfizer Inc was incorporated under the laws of the State of Delaware on June 2, 1942. It is a research-based, biopharmaceutical company. The Company applies science and its resources to bring therapies to people that extend and improve their lives through the discovery, development and manufacture of healthcare products. The Company's portfolio includes medicines and vaccines, as well as many of the world's known consumer healthcare products. The Company managed its operations through four operating segments-Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; and Consumer Healthcare. Primary Care operating segment-included revenues from prescription pharmaceutical products prescribed by primary-care physicians, and included products in the following therapeutic and disease areas: Alzheimer's disease, cardiovascular (excluding pulmonary arterial hypertension) erectile dysfunction, and genitourinary, depressive disorder, and pain, respiratory and smoking cessation. Specialty Care and Oncology operating segment-was comprised of the Specialty Care business unit and the Oncology business unit. Established Products segment included revenues from prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions. Emerging Markets-included revenues from all prescription pharmaceutical products sold in emerging markets, including Asia excluding Japan and South Korea, Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe. Consumer Healthcare operating segment-includes revenues from non-prescription products in the following therapeutic categories: dietary supplements, pain management, respiratory and personal care. In 2013, products marketed by Consumer Healthcare included Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H and Robitussin. In its biopharmaceutical businesses, the Company promotes its products to healthcare providers and patients. The Company also markets directly to consumers in the U.S. through direct-to-consumer advertising that communicates the approved uses, benefits and risks of its products while motivating people to have meaningful conversations with their doctors. Its biotechnology products, including BeneFIX, ReFacto, Xyntha, Enbrel and the Prevnar family, may face competition in the future from biosimilars. The Company competes with other companies that manufacture and sell products that treat diseases or indications similar to those treated by its products. The Company is subject to regulation by national, state and local agencies in the countries in which it does business.

Guru Investment Theses on Pfizer Inc

Gabelli Funds Comments on Pfizer Inc. - Aug 04, 2016

Pfizer Inc. (NYSE:PFE) (3.8%) (PFE – $29.64 – NYSE), headquartered in New York City, is one of the world’s largest research based pharmaceutical companies, with sales of $48.9 billion in 2015. The company’s drugs include the blockbusters Enbrel for autoimmune diseases, Lipitor for high cholesterol, Lyrica for pain, and Viagra for erectile dysfunction. The company’s late-stage pipeline includes drugs being developed to treat cancer, cardiovascular disease, and inflammatory conditions. Pfizer also offers consumer healthcare products, including Advil, Centrum, ChapStick, Emergen-C, and Robitussin. In April 2016, the company terminated its planned acquisition of Allergan plc following unfavorable tax regulations from the U.S. Treasury. Pfizer is now considering whether to split the company into two segments, one for high growth innovative pharmaceuticals and one for lower growth/declining established pharmaceuticals, with a decision expected by the end of 2016.



From the Gabelli Dividend Growth Fund second quarter 2016 commentary.



Check out Mario Gabelli latest stock trades

Top Ranked Articles about Pfizer Inc

Gilead’s Patience Is Wearing Investors' Patience Thin Despite sitting on a cash pile, the company has been slow in the acquisitions space
Gilead’s (NASDAQ:GILD) stock price has been on a never-ending slide since the second half of last year. The stock is now trading at less than 7 times earnings after dropping more than a quarter of its valuation in the last twelve months. But a key question that remains after analyzing Gilead is why the company is sitting on its cash pile without doing anything. Read more...
Which Criteria Best Determine the Success of Mergers? An evaluation of 3 recent mergers
Throughout the past three months, several mergers, including the $14 billion merger between Pfizer Inc. (NYSE:PFE) and Medivation Inc. (NASDAQ:MDVN), were announced. In part one of our study, we discussed how the John Paulson Merger Arb Checklist determines the success rate of mergers. This article will further the study by analyzing some of the recent mergers and predicting the success rate based on historical results. Read more...
Pfizer Acquires Medivation Company will pay $14 billion for biopharmaceutical business
Pfizer (NYSE:PFE) reported Monday that it would be acquiring, biopharmaceutical company, Medivation (NASDAQ:MDVN). Pfizer will pay $81.50 per share for a total value of approximately $14 billion. Shares of Medivation opened higher on Monday and gained approximately 20%. Read more...
Is Pfizer on Its Way Up? Patent expirations are countered by Hospira gains and organic growth
Pfizer (NYSE:PFE) finally had a good run this past six months. After what seemed to be an unstoppable slide in top line revenues, the company finally showed an impressive 15% increase to $26.2 billion from $22.7 billion in the year-ago six-month period. Unfortunately, the bottom line didn’t see much of that increase, and only went to $5.02 billion from $5 billion last year -- about 1% growth. Read more...
Pfizer Beats 2nd Quarter Revenue and Earnings Estimates Health care reporting good second-quarter results
Pfizer (NYSE:PFE) recently reported its second-quarter earnings with a revenue and earnings per share beat for the quarter. Pfizer is the final health care company in the Dow Jones Industrial Average to report earnings for the quarter. In the health care industry all four companies in the Dow Jones Industrial Average have beat revenue and earnings per share estimates for the quarter. Read more...
Gabelli Funds Comments on Pfizer Inc. Guru stock highlight
Pfizer Inc. (NYSE:PFE) (3.8%) (PFE – $29.64 – NYSE), headquartered in New York City, is one of the world’s largest research based pharmaceutical companies, with sales of $48.9 billion in 2015. The company’s drugs include the blockbusters Enbrel for autoimmune diseases, Lipitor for high cholesterol, Lyrica for pain, and Viagra for erectile dysfunction. The company’s late-stage pipeline includes drugs being developed to treat cancer, cardiovascular disease, and inflammatory conditions. Pfizer also offers consumer healthcare products, including Advil, Centrum, ChapStick, Emergen-C, and Robitussin. In April 2016, the company terminated its planned acquisition of Allergan plc following unfavorable tax regulations from the U.S. Treasury. Pfizer is now considering whether to split the company into two segments, one for high growth innovative pharmaceuticals and one for lower growth/declining established pharmaceuticals, with a decision expected by the end of 2016. Read more...
Pfizer Investors Mood Dampened by Second Quarter Earnings Company’s guidance holds steady, but established drugs disappointed, pulling the stock downwards
Pharma major Pfizer (NYSE:PFE) raised its earnings guidance for 2016 after the first quarter results, increasing their 2016 revenue expectation to be in the range of $51 billion to $53 billion - a full two billion higher than their previous projection of $49 billion to $51 billion. After terminating its plan for a $150 billion mega-merger with Allergan (NYSE:AGN) earlier this year, Pfizer reported 11% revenue growth for the second quarter and 15% growth during the first half of this year compared to last year. These would seem to be solid numbers, but the stocks tell us a different story. Read more...
Vanguard Sold Shares in 7 of Top 10 Quarterly Transactions Guru exited position in Pfizer in 2nd quarter
Seven of Vanguard Health Care Fund (Trades, Portfolio)’s top 10 second-quarter transactions were divestitures or reductions, including its most noteworthy deal of the quarter. Read more...
Pfizer-Allergan Merger Collapse Hurts Some Funds but Is Boosting Others Allergan's price sank but Pfizer's actually rose significantly following the merger agreement failure, a boost for long-term holders
When Pfizer Inc. (NYSE:PFE) and Allergan Plc (NYSE:AGN) announced their proposed merger deal collapsed on April 6, so too did the hopes of several influential hedge fund managers who staked much capital on its success, but some investors have seen benefits. Read more...
2 Major Mergers Come to End After Tough Stance From Regulators Treasury and Justice Department put the brakes on health care and oil deals
Two planned mega-mergers came to an end Wednesday following steps from the federal government to prevent deals that may threaten market competition. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 398.26
PFE's P/E(ttm) is ranked lower than
98% of the 537 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.49 vs. PFE: 398.26 )
Ranked among companies with meaningful P/E(ttm) only.
PFE' s P/E(ttm) Range Over the Past 10 Years
Min: 7.68  Med: 16.1 Max: 434.63
Current: 398.26
7.68
434.63
Forward P/E 12.15
PFE's Forward P/E is ranked higher than
68% of the 63 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.41 vs. PFE: 12.15 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 31.55
PFE's PE(NRI) is ranked lower than
57% of the 538 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.46 vs. PFE: 31.55 )
Ranked among companies with meaningful PE(NRI) only.
PFE' s PE(NRI) Range Over the Past 10 Years
Min: 9.83  Med: 19.14 Max: 34.43
Current: 31.55
9.83
34.43
Price/Owner Earnings (ttm) 20.59
PFE's Price/Owner Earnings (ttm) is ranked higher than
70% of the 280 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.53 vs. PFE: 20.59 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
PFE' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.44  Med: 10.92 Max: 36.49
Current: 20.59
5.44
36.49
P/B 3.06
PFE's P/B is ranked lower than
53% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. PFE: 3.06 )
Ranked among companies with meaningful P/B only.
PFE' s P/B Range Over the Past 10 Years
Min: 1.32  Med: 2.42 Max: 3.57
Current: 3.06
1.32
3.57
P/S 3.73
PFE's P/S is ranked lower than
58% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.85 vs. PFE: 3.73 )
Ranked among companies with meaningful P/S only.
PFE' s P/S Range Over the Past 10 Years
Min: 1.72  Med: 3.61 Max: 4.75
Current: 3.73
1.72
4.75
PFCF 15.44
PFE's PFCF is ranked higher than
67% of the 197 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.94 vs. PFE: 15.44 )
Ranked among companies with meaningful PFCF only.
PFE' s PFCF Range Over the Past 10 Years
Min: 5.02  Med: 13.11 Max: 17.52
Current: 15.44
5.02
17.52
POCF 13.46
PFE's POCF is ranked higher than
60% of the 268 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.41 vs. PFE: 13.46 )
Ranked among companies with meaningful POCF only.
PFE' s POCF Range Over the Past 10 Years
Min: 4.55  Med: 11.75 Max: 15.68
Current: 13.46
4.55
15.68
EV-to-EBIT 26.45
PFE's EV-to-EBIT is ranked lower than
62% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.07 vs. PFE: 26.45 )
Ranked among companies with meaningful EV-to-EBIT only.
PFE' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.7  Med: 14.4 Max: 28.8
Current: 26.45
6.7
28.8
EV-to-EBITDA 15.88
PFE's EV-to-EBITDA is ranked higher than
56% of the 562 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.70 vs. PFE: 15.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
PFE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.9  Med: 9.3 Max: 17.3
Current: 15.88
4.9
17.3
PEG 26.08
PFE's PEG is ranked lower than
95% of the 279 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.95 vs. PFE: 26.08 )
Ranked among companies with meaningful PEG only.
PFE' s PEG Range Over the Past 10 Years
Min: 0.98  Med: 3.73 Max: 1562
Current: 26.08
0.98
1562
Shiller P/E 19.28
PFE's Shiller P/E is ranked higher than
85% of the 159 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.94 vs. PFE: 19.28 )
Ranked among companies with meaningful Shiller P/E only.
PFE' s Shiller P/E Range Over the Past 10 Years
Min: 9.12  Med: 16.4 Max: 22.65
Current: 19.28
9.12
22.65
Current Ratio 1.11
PFE's Current Ratio is ranked lower than
84% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. PFE: 1.11 )
Ranked among companies with meaningful Current Ratio only.
PFE' s Current Ratio Range Over the Past 10 Years
Min: 1.11  Med: 1.65 Max: 3.18
Current: 1.11
1.11
3.18
Quick Ratio 0.89
PFE's Quick Ratio is ranked lower than
78% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.75 vs. PFE: 0.89 )
Ranked among companies with meaningful Quick Ratio only.
PFE' s Quick Ratio Range Over the Past 10 Years
Min: 0.87  Med: 1.41 Max: 2.86
Current: 0.89
0.87
2.86
Days Inventory 220.94
PFE's Days Inventory is ranked lower than
85% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.28 vs. PFE: 220.94 )
Ranked among companies with meaningful Days Inventory only.
PFE' s Days Inventory Range Over the Past 10 Years
Min: 185.33  Med: 234.41 Max: 344.63
Current: 220.94
185.33
344.63
Days Sales Outstanding 67.43
PFE's Days Sales Outstanding is ranked higher than
58% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.78 vs. PFE: 67.43 )
Ranked among companies with meaningful Days Sales Outstanding only.
PFE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.09  Med: 71.08 Max: 106.89
Current: 67.43
61.09
106.89
Days Payable 101.34
PFE's Days Payable is ranked higher than
68% of the 571 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 71.88 vs. PFE: 101.34 )
Ranked among companies with meaningful Days Payable only.
PFE' s Days Payable Range Over the Past 10 Years
Min: 73.72  Med: 107.98 Max: 179.46
Current: 101.34
73.72
179.46

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.75
PFE's Dividend Yield is ranked higher than
85% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. PFE: 3.75 )
Ranked among companies with meaningful Dividend Yield only.
PFE' s Dividend Yield Range Over the Past 10 Years
Min: 2.88  Med: 3.66 Max: 10.4
Current: 3.75
2.88
10.4
Dividend Payout 1.18
PFE's Dividend Payout is ranked lower than
74% of the 386 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.34 vs. PFE: 1.18 )
Ranked among companies with meaningful Dividend Payout only.
PFE' s Dividend Payout Range Over the Past 10 Years
Min: 0.31  Med: 0.58 Max: 10.67
Current: 1.18
0.31
10.67
Dividend Growth (3y) 8.40
PFE's Dividend Growth (3y) is ranked higher than
52% of the 286 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.00 vs. PFE: 8.40 )
Ranked among companies with meaningful Dividend Growth (3y) only.
PFE' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -14.7  Med: 13.5 Max: 22.6
Current: 8.4
-14.7
22.6
Forward Dividend Yield 3.81
PFE's Forward Dividend Yield is ranked higher than
83% of the 646 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. PFE: 3.81 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 5.90
PFE's Yield on cost (5-Year) is ranked higher than
90% of the 791 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. PFE: 5.90 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
PFE' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 4.47  Med: 5.68 Max: 16.15
Current: 5.9
4.47
16.15
3-Year Average Share Buyback Ratio 5.30
PFE's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 435 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.60 vs. PFE: 5.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PFE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.6  Med: -4 Max: 7.2
Current: 5.3
-17.6
7.2

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.98
PFE's Price/Projected FCF is ranked higher than
84% of the 307 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.77 vs. PFE: 0.98 )
Ranked among companies with meaningful Price/Projected FCF only.
PFE' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.53  Med: 1.05 Max: 8.57
Current: 0.98
0.53
8.57
Price/Median PS Value 1.02
PFE's Price/Median PS Value is ranked higher than
61% of the 615 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.14 vs. PFE: 1.02 )
Ranked among companies with meaningful Price/Median PS Value only.
PFE' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.48  Med: 1.15 Max: 3.3
Current: 1.02
0.48
3.3
Earnings Yield (Greenblatt) (%) 3.75
PFE's Earnings Yield (Greenblatt) (%) is ranked higher than
57% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. PFE: 3.75 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PFE' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.5  Med: 6.9 Max: 14.9
Current: 3.75
3.5
14.9
Forward Rate of Return (Yacktman) (%) 4.64
PFE's Forward Rate of Return (Yacktman) (%) is ranked lower than
56% of the 344 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.15 vs. PFE: 4.64 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
PFE' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 4  Med: 12.8 Max: 22.8
Current: 4.64
4
22.8

More Statistics

Revenue (TTM) (Mil) $53,244
EPS (TTM) $ 0.08
Beta0.98
Short Percentage of Float0.74%
52-Week Range $28.25 - 37.39
Shares Outstanding (Mil)6,068.36

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 52,395 54,213 54,369 51,989
EPS ($) 2.35 2.60 2.87 2.60
EPS w/o NRI ($) 2.35 2.60 2.87 2.60
EPS Growth Rate
(3Y to 5Y Estimate)
6.47%
Dividends Per Share ($) 1.18 1.24 1.85
» More Articles for PFE

Headlines

Articles On GuruFocus.com
Robust Pipeline Supports 5.5% Dividend Yield Dec 05 2016 
US Market Indexes Higher on Tuesday Nov 29 2016 
Small-Cap Biotech Is on Front Lines of Fight Against Depression Nov 22 2016 
How a 15% Decline Is a Gift to Income Investors Nov 21 2016 
3 Health Industry Sectors Bound to Profit From a Trump Presidency Nov 11 2016 
Johnson & Johnson Expect it to Deliver Consistent Results Nov 08 2016 
Allergan: Trading at a Low Earnings Multiple Nov 06 2016 
US Market Indexes Lower on Tuesday Nov 02 2016 
Seven New Stocks in My Purloined Portfolio Oct 19 2016 
Pfizer Refuses to Go the Spinoff Route Oct 17 2016 

More From Other Websites
Can't buy love? Drug price hikes put sex beyond reach Dec 05 2016
Can't buy love? Drug price hikes put sex beyond reach Dec 05 2016
Allergan's Strength Lies In Its New Products And Robust Pipeline Dec 05 2016
Robust Pipeline Supports 5.5% Dividend Yield Dec 05 2016
Pfizer (PFE) Presents Favorable Data on Leukemia Candidate Dec 05 2016
Pfizer's blood cancer drug Bosulif effective in untreated patients Dec 05 2016
Pfizer and Avillion Announce Positive Top-Line Results for Phase 3 BFORE Study of BOSULIF for... Dec 05 2016
1:57 am Pfizer reports new Phase 2 results show investigational compound Glasdegib; demonstrated... Dec 05 2016
Spark's Hemophilia Gene Therapy Remains Effective Despite Immune Reactions Dec 03 2016
New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute... Dec 03 2016
Spark Therapeutics and Pfizer Present Updated Preliminary Data from Hemophilia B Phase 1/2 Trial... Dec 03 2016
[$$] New Tax Rules on Corporate Inversions Face Uncertain Future Dec 03 2016
$50 Billion Quant Fund Is Making New Bets On These Stocks Dec 02 2016
The Numbers Behind a Pharma CEO Shouting Match Dec 02 2016
Morgan Stanley: Chevron, Pfizer Will be Big Winners in 2017 Dec 02 2016
[$$] Tax Rules on Corporate Inversions Face Uncertain Future Dec 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)